June 2, 2020 / 6:06 AM / a month ago

BRIEF-Synact Pharma's Clinical Trial Approved By The Danish Medical Agency

June 2 (Reuters) - SynAct Pharma AB:

* SYNACT PHARMA’S CLINICAL TRIAL APPLICATION FOR AP1189 IN NEPHROTIC SYNDROME APPROVED BY THE DANISH MEDICAL AGENCY

* SYNACT PHARMA AB - IN PHASE IIA STUDY, AP1189 WILL BE TESTED IN A DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTRE STUDY AS ADD-ON THERAPY TO ACE-INHIBITOR OR ANGIOTENSIN-2 RECEPTOR ANTAGONISTS

* SYNACT PHARMA AB - TO INITIATE PHASE IIA-STUDY IN NS BY END OF JUNE 2020 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below